Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy

Mayo Clin Proc. 2024 Feb;99(2):341-343. doi: 10.1016/j.mayocp.2023.11.019.
No abstract available

MeSH terms

  • Benzylamines
  • Cardiomyopathy, Hypertrophic* / drug therapy
  • Cardiomyopathy, Hypertrophic* / genetics
  • Genotype
  • Humans
  • Uracil

Substances

  • MYK-461
  • Benzylamines
  • Uracil